GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Price-to-Owner-Earnings

ZyVersa Therapeutics (ZyVersa Therapeutics) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Price-to-Owner-Earnings?

As of today (2024-06-09), ZyVersa Therapeutics's share price is $4.41. ZyVersa Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ZyVersa Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ZVSA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), ZyVersa Therapeutics's share price is $4.41. ZyVersa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1,762.95. Therefore, ZyVersa Therapeutics's PE Ratio for today is At Loss.

As of today (2024-06-09), ZyVersa Therapeutics's share price is $4.41. ZyVersa Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-287.05. Therefore, ZyVersa Therapeutics's PE Ratio without NRI for today is At Loss.


ZyVersa Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for ZyVersa Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Price-to-Owner-Earnings Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

ZyVersa Therapeutics Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ZyVersa Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, ZyVersa Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZyVersa Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Price-to-Owner-Earnings falls into.



ZyVersa Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ZyVersa Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.41/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ZyVersa Therapeutics  (NAS:ZVSA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ZyVersa Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Executives
Pablo A. Guzman officer: Chief Medical Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein director 1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover director, officer: Chief Executive Officer 108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr. officer: Chief Scientific Officer C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe officer: Chief Financial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere officer: Chief Commercial Officer C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park director C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd. 10 percent owner 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones director, officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor director, officer: Chief Executive Officer C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp. 10 percent owner 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880

ZyVersa Therapeutics (ZyVersa Therapeutics) Headlines

From GuruFocus